Read more
Integrating CAR T-Cell Therapy with HDT/ASCT: A Synergistic Strategy for Relapsed/Refractory LBCL — Insights from Chinese Oncology Practice

Introduction: Tackling the Refractory Frontier in LBCL Relapsed or refractory large B-cell lymphoma (R/R LBCL) continues to pose significant clinical challenges, especially after failure of frontline chemoimmunotherapy. In China, the incidence of non-Hodgkin lymphoma, including aggressive subtypes like LBCL, is on the rise due to an aging population and environmental factors. In recent years, CAR T-cell therapy—particularly CD19-targeted constructs like relma-cel (developed in China)—has demonstrated impressive remission rates. Meanwhile, high-dose …